Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press30210.17650/1726-9776-2009-5-4-58-62DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫNEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCERНОВЫЕ ТЕНДЕНЦИИ В ПРИМЕНЕНИИ ТАКСОТЕРА (ДОЦЕТАКСЕЛА) ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫKaryakinO. B.КарякинО. Б.
Russian Federation
karyakin@mrrc.obninsk.ruBiryukovV. A.БирюковВ. А.
Russian Federation
karyakin@mrrc.obninsk.ruMedical Radiology Research Center, Russian Academy of Medical Sciences, ObninskМедицинский радиологический научный центр РАМН, Обнинск301220095458620508201405082014https://oncourology.abvpress.ru/oncur/article/view/302

The papers on studies of the efficacy of Taxotere in prostate cancer (PC) are reviewed. The use of Taxotere is shown to increase survival in patients with metastatic hormone-refractory PC. Taxoterebased neoadjuvant and adjuvant chemotherapies are rather safe and have no sig nificant impact on further surgical and radiation therapies in patients with PC.

 

Проведен обзор работ, посвященных исследованию эффективности Таксотера при раке предстательной железы (РПЖ). Показано, что применение Таксотера способствует увеличению выживаемости больных метастатическим гормонорефрактерным РПЖ. Неоадъювантная и адъювантная химиотерапия на основе Таксотера эффективна, достаточно безопасна и не оказывает значимого влияния на последующее хирургическое и лучевое лечение больных РПЖ.

 

prostate cancerchemotherapyTaxotereрак предстательной железыхимиотерапияТаксотер1. Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110.Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110.2. Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910.Roehl K.A., Han M., Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910.3. Bolla M., Collette L., Blank L. et al. Long-term resides with immediate androgen suppression and external irradiation in patients with iocally advanced prostate cancer (an EORTC study): a phase III ran- domised trial. Lancet 2002;360:103—6.Bolla M., Collette L., Blank L. et al. Long-term resides with immediate androgen suppression and external irradiation in patients with iocally advanced prostate cancer (an EORTC study): a phase III ran- domised trial. Lancet 2002;360:103—6.4. Klotz L.H., Goldenberg S.L., Jewett M.A. et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791.Klotz L.H., Goldenberg S.L., Jewett M.A. et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791.5. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prosta tectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781—8.Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prosta tectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781—8.6. Tannock I.E., de Wit R., Berry W.R. et at. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502—12.Tannock I.E., de Wit R., Berry W.R. et at. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502—12.7. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513—20.Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513—20.8. Fair W.R., Betancourt J.E. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol 2000;4:241—50.Fair W.R., Betancourt J.E. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol 2000;4:241—50.9. Qleave M., Goldenberg S., Chin J. et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003;169:690A.Qleave M., Goldenberg S., Chin J. et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003;169:690A.10. Klotz L.H., Goldenberg S.L., Jewett M.A. et al. Canadian Uro-Oncology Group, Long-term followupof a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791—4.Klotz L.H., Goldenberg S.L., Jewett M.A. et al. Canadian Uro-Oncology Group, Long-term followupof a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791—4.11. Soloway M.S., Sharifi R., Wajsman Z. et al. Randomized prospective study com- paring radical prostatectomyaloneversus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424—8.Soloway M.S., Sharifi R., Wajsman Z. et al. Randomized prospective study com- paring radical prostatectomyaloneversus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424—8.12. Goldenberg S.L., Klotz L.H., Srigley J. et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdraw- al in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996;156:873—7.Goldenberg S.L., Klotz L.H., Srigley J. et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdraw- al in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996;156:873—7.13. Aus G., Abrahamsson P., Ahlgren G. et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 1998;159:2013—7.Aus G., Abrahamsson P., Ahlgren G. et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 1998;159:2013—7.14. Winquist J.E., Chi K.N., Chin J. et al. Multicenter phase II study of combined docetaxel and neoadjuvant hormone therapy (NHT) prior to prostatectomy for patients with high risk localized prostate cancer: pathologic outcomes and 3-year follow-up analyses. Clin Oncol ASCO Ann Meeting Proc 2007;25:18. Abstr 5002.Winquist J.E., Chi K.N., Chin J. et al. Multicenter phase II study of combined docetaxel and neoadjuvant hormone therapy (NHT) prior to prostatectomy for patients with high risk localized prostate cancer: pathologic outcomes and 3-year follow-up analyses. Clin Oncol ASCO Ann Meeting Proc 2007;25:18. Abstr 5002.15. Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500—6.Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500—6.16. Hussain M., Smith D.C., El-Rayes B.F. et al. Neoadjuvant docetaxel and estramuslme chemotherapy in high- risk/ locally advanced prostate cancer. Urology 2003;61:774—80.Hussain M., Smith D.C., El-Rayes B.F. et al. Neoadjuvant docetaxel and estramuslme chemotherapy in high- risk/ locally advanced prostate cancer. Urology 2003;61:774—80.17. Prayer-Galetti T., Saccot E., Pagano F. et al. Long-term follow-up of a neoadjuvant chemohormonal taxanebased phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate can- cer. BJU Intern 2007;100:274—80.Prayer-Galetti T., Saccot E., Pagano F. et al. Long-term follow-up of a neoadjuvant chemohormonal taxanebased phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate can- cer. BJU Intern 2007;100:274—80.18. Sella А., Zisman А., Kovel S. et al. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008:71(2):323—7.Sella А., Zisman А., Kovel S. et al. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008:71(2):323—7.19. Dreicer R., Magi-Galluzzi C., Zhou M. et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004:63:138—42.Dreicer R., Magi-Galluzzi C., Zhou M. et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004:63:138—42.20. Febbo P.G., Richie J.P., George D.J. et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233—40.Febbo P.G., Richie J.P., George D.J. et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233—40.21. Garzotto M., Myrthue A., Higano C.S., Beer T.M. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24:254—9.Garzotto M., Myrthue A., Higano C.S., Beer T.M. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24:254—9.22. Friedman J.D., Dunn R., Wood D. et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179:911—6.Friedman J.D., Dunn R., Wood D. et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179:911—6.23. Bolla M., van Poppel H., Collette L. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572.Bolla M., van Poppel H., Collette L. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572.24. Thompson I.M. Jr., Tangen C.M., Paradelo J. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329.Thompson I.M. Jr., Tangen C.M., Paradelo J. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329.25. Schmidt J.D., Gibbons R.P., Murphy G.P., Bartolucci A. Adjuvant ther- apy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996;29:425—33.Schmidt J.D., Gibbons R.P., Murphy G.P., Bartolucci A. Adjuvant ther- apy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996;29:425—33.26. Wang J., Halford S., Rigg A. et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675—80.Wang J., Halford S., Rigg A. et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675—80.27. Skinner E.C., Glode L.M. High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol 2003;21:219.Skinner E.C., Glode L.M. High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol 2003;21:219.28. Narayan S., Smith D.C., Sandler H.M. Chemotherapy for localized, high-risk prostate cancer. Semin Radiat Oncol 2003;13:152.Narayan S., Smith D.C., Sandler H.M. Chemotherapy for localized, high-risk prostate cancer. Semin Radiat Oncol 2003;13:152.29. Kibel A.S., Rosenbaum E., Kattan M.W. et al. Adjuvant weekly Docetaxel for patients with high risk prostate cancer after radical prostatectomy. A multi-institutional pilot study. J Urol 2007;177:1777—81.Kibel A.S., Rosenbaum E., Kattan M.W. et al. Adjuvant weekly Docetaxel for patients with high risk prostate cancer after radical prostatectomy. A multi-institutional pilot study. J Urol 2007;177:1777—81.30. Hussain A., Dawson N., Amin P. et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-spe- cific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23:2789—96.Hussain A., Dawson N., Amin P. et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-spe- cific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23:2789—96.31. Taplin M.-E., Xie W., Bubley G. et al. Docetaxel, Estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24:5408—13.Taplin M.-E., Xie W., Bubley G. et al. Docetaxel, Estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24:5408—13.32. Robert J., Amato R.J., Teh B.S. et al. A retrospective review of combination chemohormonal therapy as initial treat- ment for locally advanced or metastatic adenocarcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations, 2007.Robert J., Amato R.J., Teh B.S. et al. A retrospective review of combination chemohormonal therapy as initial treat- ment for locally advanced or metastatic adenocarcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations, 2007.33. Calabro F., Sternberg C. Current indi- cations for chemotherapy in prostate can- cer patients. Eur Urol 2007;51:17—26.Calabro F., Sternberg C. Current indi- cations for chemotherapy in prostate can- cer patients. Eur Urol 2007;51:17—26.34. Sonpavde G., Chi K., Powles Т. et al. Neoadjuvant therapy followed by prostatec- tomy for clinically localized prostate can- cer. Cancer 2007;110: 2628—39.Sonpavde G., Chi K., Powles Т. et al. Neoadjuvant therapy followed by prostatec- tomy for clinically localized prostate can- cer. Cancer 2007;110: 2628—39.35. Vuky J., Porter C., Isacson C. et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. 2006 Multidisciplinary Prostate Cancer Symposium, San Francisco, California, February 24—26, 2006. Abstr 80.Vuky J., Porter C., Isacson C. et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. 2006 Multidisciplinary Prostate Cancer Symposium, San Francisco, California, February 24—26, 2006. Abstr 80.36. Shariat S.F., Anwuri V.A., Lamb D.I. et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion mole- cule-1 with lymph node status and bio- chemical progression after radical prostate- ctomy. J Clin Oncol 2004;22:1655—63.Shariat S.F., Anwuri V.A., Lamb D.I. et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion mole- cule-1 with lymph node status and bio- chemical progression after radical prostate- ctomy. J Clin Oncol 2004;22:1655—63.